United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark

Key Takeaways United Therapeutics' Q3 EPS rose 12% to $7.16, which topped expectations but revenues missed.Overall Tyvaso sales climbed 10% year over year, led by 22% growth in Tyvaso DPI.TETON-2 study showed Tyvaso improved lung function in IPF patients, supporting future growth.United Therapeutics (UTHR) reported third-quarter 2025 earnings of $7.16 per share, which beat the Zacks Consensus Estimate of $6.89. Earnings rose 12% year over year on the back of higher product sales.United Therapeutics markets ...